Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1147 articles about Moderna, Inc.
-
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
3/10/2021
Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa
-
Moderna Named Fast Company’s Most Innovative Company for 2021
3/9/2021
Moderna Named Fast Company ’s Most Innovative Company for 2021 Moderna ranked number 1 overall; also ranked number 1 in the biotechnology category
-
In a list of the most innovative vaccine makers in 2021, Fast Company has outlined 10 biotech companies that continue to revolutionize the drug-discovery landscape.
-
Shannon Thyme Klinger Joins Moderna as Chief Legal Officer and Corporate Secretary
3/8/2021
Moderna Inc., Moderna , Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Shannon Thyme Klinger will join the Company as Chief Legal Officer, effective June 1, 2021. She will serve on Moderna’s Executive Committee and as Corporate Secretary and report to Chief Executive Officer Stéphane Bancel.
-
Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
3/8/2021
Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,
-
Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines
3/6/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced a supply agreement with the Government of The Philippines for 13 million doses of the COVID-19 Vaccine Moderna.
-
Moderna Announces New Drug Application Submitted to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan
3/5/2021
50 million doses of Moderna’s COVID-19 vaccine candidate expected to be distributed beginning in the first half of 2021, pending licensure in Japan
-
GC Pharma Finalises Agreement With Moderna and the Government of the Republic of Korea for COVID-19 Vaccines Distribution
3/4/2021
GC Pharma announced that it will support Moderna and the government of the Republic of Korea in the distribution of 40 million doses of COVID-19 Vaccine Moderna, Moderna’s vaccine candidate against COVID-19, to support South Korea’s aim of providing vaccines to the public in a timely manner, subject to necessary local regulatory approvals.
-
Moderna and IBM Plan to Collaborate on COVID-19 Vaccine Supply Chain and Distribution Data Sharing
3/4/2021
Today, Moderna (Nasdaq: MRNA) and IBM (NYSE: IBM) announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine management.
-
On Sunday, Reuters reported the U.K. pharma giant sold off its 7.7% stake in the company for more than $1 billion.
-
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
2/25/2021
2021 Vaccine Manufacturing: Raises lower end of global manufacturing plan for 2021 from 600 million doses to 700 million doses; manufacturing is still working to supply up to 1 billion doses for 2021
-
Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine
2/24/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces it is making new capital investments to increase capacity at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to approximately 1.4 billion doses of its COVID-19 vaccine, assuming a 100 μg dose.
-
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study
2/24/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351,
-
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
2/24/2021
Takeda is making two COVID-19 vaccines available in Japan, by manufacturing Novavax’ recombinant vaccine candidate and by distributing Moderna’s mRNA vaccine candidate, with the support of the Japanese Government
-
Moderna to Present at Upcoming Investor Conferences in February and March 2021
2/18/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:
-
Moderna Provides U.S. COVID-19 Vaccine Supply Update - Feb 16, 2021
2/16/2021
The CDC communicated that approximately 25.5 million doses of the Moderna COVID-19 Vaccine have been administered in the U.S.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
-
U.S. Government Purchases Additional 100 Million Doses of Moderna’s COVID-19 Vaccine
2/11/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the U.S. government has purchased an additional 100 million doses of Moderna’s COVID-19 Vaccine, bringing its confirmed order commitment to 300 million doses.
-
Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses
2/9/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses. Under the terms of the agreements, deliveries would begin in mid-2021.
-
Moderna to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 25, 2021
2/4/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,